Gould James, Alexander Ian, Tomkin Edward, Brodner David
St. Louis Sinus Center, St. Louis, Missouri, USA.
Am J Rhinol Allergy. 2014 Mar-Apr;28(2):156-63. doi: 10.2500/ajra.2014.28.4043. Epub 2014 Feb 14.
The objective of this prospective, multicenter study was to assess 1-year changes in sinonasal symptoms and health care use after office-based multisinus balloon dilation.
Adults diagnosed with chronic or recurrent acute rhinosinusitis per the 2007 adult sinusitis guidelines were enrolled in this Institutional Review Board-approved study. Balloon dilation of the maxillary sinuses/ethmoid infundibula with or without frontal or sphenoid ostial dilation was performed in the physician's office under local anesthesia. Intraoperative procedure technical success and subject procedure tolerance were recorded. Efficacy was assessed using the patient-reported 20-item Sino-Nasal Outcome Test (SNOT-20) and Rhinosinusitis Symptom Inventory (RSI). Complications and revision surgeries were also recorded.
A total of 313 ostial dilations were attempted and 307 were successfully completed (98.1%) in 81 subjects. Mean procedure tolerance was 2.8 ± 2.2 (0 = no pain; 10 = severe pain). Clinically meaningful and statistically significant (p < 0.0001) mean SNOT-20 symptom improvement was observed at 1 and 6 months and sustained through 1 year. The RSI treatment effect for all major rhinosinusitis symptoms was "large" and improvement in each was significant (p < 0.0001). Compared with the previous 1-year period, patients reported an average of 2.3 fewer acute sinus infections (p < 0.0001), 2.4 fewer antibiotic courses taken (p < 0.0001), and 3.0 fewer sinus-related physician visits (p < 0.0001) after balloon dilation. No serious device or procedure-related adverse events occurred. One subject (1.3%) underwent revision surgery.
In-office, multisinus balloon dilation is safe, effective, and well tolerated. Patients reported significant reductions in both sinonasal symptoms and health care use after balloon dilation. Efficacy observed at 1 and 6 month follow-up was sustained through 1 year with a very low rate of revision surgery. This study was a part of the clinical trial NCT01612780 registered at www.clinicaltrials.gov.
这项前瞻性多中心研究的目的是评估门诊多鼻窦球囊扩张术后1年鼻窦症状和医疗保健使用情况的变化。
根据2007年成人鼻窦炎指南诊断为慢性或复发性急性鼻窦炎的成年人被纳入这项经机构审查委员会批准的研究。在局部麻醉下,由医生在诊室对上颌窦/筛漏斗进行球囊扩张,可选择同时或不同时扩张额窦或蝶窦开口。记录术中操作技术成功率和受试者对操作的耐受性。使用患者报告的20项鼻窦结局测试(SNOT-20)和鼻窦炎症状量表(RSI)评估疗效。记录并发症和翻修手术情况。
共对81名受试者进行了313次开口扩张尝试,其中307次成功完成(98.1%)。平均操作耐受性为2.8±2.2(0表示无疼痛;10表示剧痛)。在1个月和6个月时观察到具有临床意义且有统计学显著性(p<0.0001)的平均SNOT-20症状改善,并持续至1年。RSI对所有主要鼻窦炎症状的治疗效果为“显著”,且每种症状的改善均具有显著性(p<0.0001)。与前1年相比,患者报告球囊扩张术后急性鼻窦感染平均减少2.3次(p<0.0001),抗生素疗程平均减少2.4个(p<0.0001),与鼻窦相关的医生就诊平均减少3.0次(p<0.0001)。未发生严重的器械或操作相关不良事件。1名受试者(1.3%)接受了翻修手术。
门诊多鼻窦球囊扩张术安全、有效且耐受性良好。患者报告球囊扩张术后鼻窦症状和医疗保健使用均显著减少。在1个月和6个月随访时观察到的疗效持续至1年,翻修手术率极低。本研究是在www.clinicaltrials.gov注册的临床试验NCT01612780的一部分。